A randomized controlled trial of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in Northern Tanzania

Table 3 Associations with death and receipt of antituberculous treatment among 70 participants with suspect tuberculosis Tanzania, 2008-9

	All	Anti-TB	No anti-TB	OR	p
All	70	22 (31)*†	48 (68)
Death before 2 weeks	9 (13)	1 (4)	8 (17)	0.25 (0.03–2.0)	0.25
Any death	18 (26)	2 (9)	16 (33)	0.2 (0.04–0.96)	0.04
Pediatric	23	7 (30)	16 (69)
Death before 2 weeks	2 (9)	1 (14)	1 (6)	2.5 (0.13–46.8)	0.53
Any death	4 (17)	1 (14)	3 (19)	0.72 (0.06–8.5)	0.66
Adult	47	15 (32)	32 (68)
Death before 2 weeks	7 (15)	0	7 (22)	undefined	0.08
Any death	14 (30)	1 (7)	13 (41)	0.10 (0.01–0.89)	0.02
HIV-infected	34	10 (29)	24 (71)
Death before 2 weeks	5 (15)	0	5 (21)	undefined	0.29
Any death	9 (26)	0	9 (38)	undefined	0.01
Smear-negative	59	13 (22)	46 (78)
Death before 2 weeks	7 (12)	0	7 (15)	undefined	0.33
Any death	15 (25)	1 (8)	14 (30)	0.19 (0.02–1.6)	0.15
Standard arm	37	12 (32)	25 (68)
Death before 2 weeks	4 (11)	0	4 (19)	undefined	0.19
Any death	9 (24)	1 (8)	8 (32)	0.19 (0.05–1.5)	0.12
Intensified arm	33	10 (30)	23 (70)
Death before 2 weeks	5 (15)	1 (10)	4 (17)	0.53 (0.20–1.4)	0.29
Any death	9 (27)	1 (10)	8 (35)	0.20 (0.00–1.4)	0.15

*An additional 2 patients were prescribed anti–TB but died before initiating therapy.
†Percentages refer to proportion of total in each category.
p–values in bold are statistically significant at a level of p<0.05.

ISSN: 1471-2334